Amino Acid, Peptide, or Protein – Page 53

FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery

9 months ago talkbio0Tagged Approved, AstraZeneca, durvalumab, Imfinzi, Immunologic Adjuvants, Malignant neoplasm of lung, Neoadjuvant Therapy, Non-Small Cell Lung Carcinoma, Surgery specialty, United States Food and Drug Administration

FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC

England’s NICE Approves Theramex’s Uterine Fibroids Treatment

9 months ago talkbio0Tagged Antagonist muscle action, gonadorelin, hormonal add-back therapy, linzagolix, Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Theramex, Uterine Fibroids, women 's, Yselty

NICE, Theramex, uterine fibroids, linzagolix, Yselty, GnRH antagonist, hormonal add-back therapy, NHS, women’s health

Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma

9 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, expansion, Incyte, Labels (device), Lymphoma, Follicular, Monjuvi, MorphoSys, Phase 3 Clinical Trials, tafasitamab, United States Food and Drug Administration

Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.

Bavarian Nordic Returns to the Spotlight as Mpox Outbreak Reaches Emergency State

9 months ago talkbio0Tagged Bavarian Nordic, declaration, Emergency State, mpox outbreak, production, public health medicine (field), Vaccines, World Health Organization

Bavarian Nordic, mpox outbreak, emergency state, vaccine production, WHO declaration, public health emergency

Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges

9 months ago talkbio0Tagged Approved, China, competition, Expiration, function, Legal patent, Nordisk, Obesity, pharmaceutical market, semaglutide, Wegovy

Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

9 months ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection

9 months ago talkbio0Tagged Clinical Research, COMBINE-1, File (record), Icodec, IcoSema, Insulin, Nordisk, once-weekly, regulatory approval, semaglutide, United States Food and Drug Administration

Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval

Acelyrin Shifts Focus Amid Izokibep Setbacks, Lays Off Staff to Pursue Tepezza’s Market Share

9 months ago talkbio0Tagged Acelyrin, Clinical Trials, Izokibep, Market, setbacks, Strategy, Tepezza

Acelyrin, izokibep, clinical trial setbacks, layoffs, Tepezza, market strategy

Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns

9 months ago talkbio0Tagged Icodec, IcoSema, Insulin, Nordisk, once-weekly, Rejection (Psychology), semaglutide, United States Food and Drug Administration

Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema

23andMe Shifts Focus to GLP-1 Telehealth Offering, Cuts Internal Drug Development Team

9 months ago talkbio0Tagged Drug Development, Glucagon-Like Peptide 1, Telemedicine

23andMe, GLP-1, telehealth, weight loss, drug development, layoffs